KED Peptide: Research in Cellular Aging Models

KED (Lys-Glu-Asp) is a synthetic tripeptide and Khavinson bioregulator developed at the Saint Petersburg Institute of Bioregulation, classified as an "immune peptide bioregulator" targeting thymic and immune tissue function in the aging immune system.

Immunosenescence: The Research Context

The immune system undergoes progressive functional decline with aging — characterised by:

• Thymic involution: progressive reduction in naive T cell output beginning in adolescence
• Accumulation of exhausted CD8+ T cells with low telomerase activity
• Reduced antibody diversity and affinity maturation
• Chronic low-grade inflammation ("inflammaging") from senescent cells and viral reactivation

The result is impaired responses to novel antigens and reduced tumor immune surveillance — major contributors to aging-related morbidity. For established immune peptide research, Thymosin Alpha-1 has Phase 3 RCT data and regulatory approval in 35+ countries for viral hepatitis and immune reconstitution — a much higher evidence bar than KED.

KED's Proposed Mechanism

KED (Lys-Glu-Asp) is proposed to bind chromatin in a sequence-preferential manner, reactivating gene expression of immune-regulatory proteins that decline with aging. Target genes include:

• IL-2 and IL-2 receptor (critical for T cell proliferation)
• IL-7 receptor (essential for naive T cell survival)
• TERT in T lymphocytes (restoring replicative capacity)

In vitro evidence from Khavinson's group (10-100 ng/mL KED):

• IL-2 production in PHA-stimulated human lymphocytes: increased approximately 25-35%
• Proportion of cells in S-phase in aged donor lymphocyte cultures: increased (enhanced replicative potential)
• Apoptotic markers in oxidatively stressed lymphocytes: reduced

Animal Model Data

In aged C57BL/6 mice (20-22 months), KED at 1 mcg/kg SC for 10 days:

• CD4+/CD8+ T cell ratio: improved toward young-adult levels
• NK cell cytotoxic activity: increased (chromium release assay)
• Antibody response to a T cell-dependent antigen challenge: improved

KED vs Thymosin Alpha-1

Thymosin Alpha-1 has robust Western RCT data (published in *Gastroenterology*, *Nature Communications*, *Frontiers in Medicine*), regulatory approval in 35+ countries, and a well-characterised TLR2/TLR9 mechanism. KED has preclinical data and Russian observational studies only. For research requiring the most established immune-stimulatory peptide, Thymosin Alpha-1 is the clear choice. KED's research interest lies primarily within the Khavinson bioregulator framework.

KED is a research compound with limited evidence base outside of the Khavinson research programme.

<!-- deep-links-v1 -->

Related Neuroprotective and Cognitive Aging Peptides

KED's cellular aging research intersects with a wide range of neuroprotective and cognitive compounds. FGL Peptide (NCAM-derived fibronectin loop peptide) activates FGFR signaling to promote synaptic plasticity and neuroprotection — a mechanistic complement to KED's chromatin-level effects. Crystagen addresses the visual cortex and lens aging dimensions. Cerluten, the cerebral cortex bioregulator, is studied for age-related cognitive function support in the same animal models used for KED. Pinealon (Glu-Asp-Arg) activates neuroprotective gene expression in brain aging models, with particular activity in the pineal and visual cortex. P21 is a CXCR4-derived peptide with documented effects on hippocampal neurogenesis in aging rodent models. Dihexa, an angiotensin IV analogue, promotes synaptogenesis through HGF/c-Met signaling — among the most potent pro-cognitive peptides in the preclinical literature. PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide) drives neurotrophin release and neuroprotection in ischemia and aging models. PE-22-28 is a TREK-1 channel inhibitor with rapid antidepressant and neuroplasticity effects. Cerebrolysin, a peptide mixture derived from pig brain, has clinical data supporting cognitive improvement in Alzheimer's disease models.